Pazopanib

Generic Name
Pazopanib
Brand Names
Votrient
Drug Type
Small Molecule
Chemical Formula
C21H23N7O2S
CAS Number
444731-52-6
Unique Ingredient Identifier
7RN5DR86CK
Background

Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

Indication

Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)

Associated Conditions
Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer
Associated Therapies
-

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

First Posted Date
2018-07-19
Last Posted Date
2024-01-23
Lead Sponsor
Xynomic Pharmaceuticals, Inc.
Target Recruit Count
413
Registration Number
NCT03592472
Locations
🇪🇸

H.U. Virgen de la Victoria, Málaga, Spain

🇪🇸

H.G.U. de Elche, Elche, Spain

🇪🇸

Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain

and more 35 locations

Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors

First Posted Date
2018-06-27
Last Posted Date
2020-01-18
Lead Sponsor
University Hospital, Grenoble
Target Recruit Count
100
Registration Number
NCT03571438
Locations
🇫🇷

Grenoble Alps Hospital, Grenoble, France

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

First Posted Date
2017-08-24
Last Posted Date
2024-04-11
Lead Sponsor
Incyte Corporation
Target Recruit Count
129
Registration Number
NCT03260894
Locations
🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

🇺🇸

Rush University Medical Center, Chicago, Illinois, United States

🇨🇦

Sunnybrook Health Sciences, Odette Cancer Centre, Toronto, Ontario, Canada

and more 137 locations

Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment

First Posted Date
2017-06-27
Last Posted Date
2023-08-21
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
62
Registration Number
NCT03200717
Locations
🇬🇧

Novartis Investigative Site, Preston, United Kingdom

🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas

Phase 2
Withdrawn
Conditions
Interventions
First Posted Date
2017-05-11
Last Posted Date
2017-08-22
Lead Sponsor
NYU Langone Health
Registration Number
NCT03149120
Locations
🇺🇸

New York University School of Medicine, New York, New York, United States

PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma

First Posted Date
2017-05-03
Last Posted Date
2021-01-05
Lead Sponsor
University of California, San Francisco
Target Recruit Count
16
Registration Number
NCT03139331
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

🇺🇸

UCSF Benioff Children's Hospital, Oakland, Oakland, California, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma

Phase 3
Completed
Conditions
Interventions
First Posted Date
2016-12-02
Last Posted Date
2020-05-12
Lead Sponsor
Tracon Pharmaceuticals Inc.
Target Recruit Count
128
Registration Number
NCT02979899
Locations
🇺🇸

University of Washinton, Seattle, Washington, United States

🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

🇺🇸

MD Anderson, Houston, Texas, United States

and more 36 locations

A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer

First Posted Date
2016-11-10
Last Posted Date
2021-04-26
Lead Sponsor
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Target Recruit Count
200
Registration Number
NCT02960906
Locations
🇫🇷

Centre Francois Baclesse, Caen, France

🇫🇷

Hôpital Cochin, Paris, France

🇫🇷

Centre Antoine Lacassagne, Nice, France

and more 13 locations

Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control

First Posted Date
2016-11-09
Last Posted Date
2021-09-08
Lead Sponsor
AIO-Studien-gGmbH
Target Recruit Count
49
Registration Number
NCT02959554
Locations
🇩🇪

Universitätsklinikum Essen (AöR) - Klinik und Poliklinik für Urologie / Kinderurologie und Uroonkologie, Essen, Germany

🇦🇹

Medizinische Universität Wien - Universitätsklinik für Innere Medizin I, Klinische Abteilung für Onkologie, Wien, Austria

Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer

First Posted Date
2016-06-10
Last Posted Date
2019-10-24
Lead Sponsor
Virginia Commonwealth University
Target Recruit Count
6
Registration Number
NCT02795819
Locations
🇺🇸

Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States

© Copyright 2024. All Rights Reserved by MedPath